Schnoll SH - Search Results

1

An analysis of the root causes for opioid-related overdose deaths in the United States.

Webster LR, Cochella S, Dasgupta N, Fakata KL, Fine PG, Fishman SM, Grey T, Johnson EM, Lee LK, Passik SD, Peppin J, Porucznik CA, Ray A, Schnoll SH, Stieg RL, Wakeland W. Webster LR, et al. Among authors: schnoll sh. Pain Med. 2011 Jun;12 Suppl 2:S26-35. doi: 10.1111/j.1526-4637.2011.01134.x. Pain Med. 2011. PMID: 21668754

2

Challenges in the development of prescription opioid abuse-deterrent formulations.

Katz NP, Adams EH, Chilcoat H, Colucci RD, Comer SD, Goliber P, Grudzinskas C, Jasinski D, Lande SD, Passik SD, Schnoll SH, Sellers E, Travers D, Weiss R. Katz NP, et al. Among authors: schnoll sh. Clin J Pain. 2007 Oct;23(8):648-60. doi: 10.1097/AJP.0b013e318125c5e8. Clin J Pain. 2007. PMID: 17885342 Review.

3

When drugs in the same controlled substance schedule differ in real-world abuse, should they be differentiated in labeling?

Dasgupta N, Henningfield JE, Ertischek MD, Schnoll SH. Dasgupta N, et al. Among authors: schnoll sh. Drug Alcohol Depend. 2011 Dec 1;119(1-2):e1-4. doi: 10.1016/j.drugalcdep.2011.05.013. Epub 2011 Jun 24. Drug Alcohol Depend. 2011. PMID: 21704462

4

Real-world misuse, abuse, and dependence of abuse-deterrent versus non-abuse-deterrent extended-release morphine in Medicaid non-cancer patients.

Cicero TJ, Mendoza M, Cattaneo M, Dart RC, Mardekian J, Polson M, Roland CL, Schnoll SH, Webster LR, Park PW. Cicero TJ, et al. Among authors: schnoll sh. Postgrad Med. 2019 Apr;131(3):225-229. doi: 10.1080/00325481.2019.1585688. Epub 2019 Mar 19. Postgrad Med. 2019. PMID: 30794760

5

Signal detection in post-marketing surveillance for controlled substances.

Dasgupta N, Schnoll SH. Dasgupta N, et al. Among authors: schnoll sh. Drug Alcohol Depend. 2009 Dec 1;105 Suppl 1:S33-41. doi: 10.1016/j.drugalcdep.2009.05.019. Epub 2009 Jul 18. Drug Alcohol Depend. 2009. PMID: 19616902 Review.

6

Epidemiology of stimulant misuse and abuse: implications for future epidemiologic and neuropharmacologic research.

Gerlach KK, Dasgupta N, Schnoll SH, Henningfield JE. Gerlach KK, et al. Among authors: schnoll sh. Neuropharmacology. 2014 Dec;87:91-6. doi: 10.1016/j.neuropharm.2014.04.020. Epub 2014 May 9. Neuropharmacology. 2014. PMID: 24813641 Review.

7

Do prescription monitoring programs impact state trends in opioid abuse/misuse?

Reifler LM, Droz D, Bailey JE, Schnoll SH, Fant R, Dart RC, Bucher Bartelson B. Reifler LM, et al. Among authors: schnoll sh. Pain Med. 2012 Mar;13(3):434-42. doi: 10.1111/j.1526-4637.2012.01327.x. Epub 2012 Feb 2. Pain Med. 2012. PMID: 22299725

8

Do abuse deterrent opioid formulations work?

Dart RC, Iwanicki JL, Dasgupta N, Cicero TJ, Schnoll SH. Dart RC, et al. Among authors: schnoll sh. J Opioid Manag. 2017 Nov/Dec;13(6):365-378. doi: 10.5055/jom.2017.0415. J Opioid Manag. 2017. PMID: 29308584 Review.

9

Surveillance of diversion and nonmedical use of extended-release prescription amphetamine and oral methylphenidate in the United States.

Sembower MA, Ertischek MD, Buchholtz C, Dasgupta N, Schnoll SH. Sembower MA, et al. Among authors: schnoll sh. J Addict Dis. 2013;32(1):26-38. doi: 10.1080/10550887.2012.759880. J Addict Dis. 2013. PMID: 23480245 Free PMC article.

10

The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS).

Cicero TJ, Dart RC, Inciardi JA, Woody GE, Schnoll S, Muñoz A. Cicero TJ, et al. Pain Med. 2007 Mar;8(2):157-70. doi: 10.1111/j.1526-4637.2006.00259.x. Pain Med. 2007. PMID: 17305687

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

108 results

Search Page